+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Acute Agitation and Aggression Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896127
  • Report
  • January 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Holdings
  • MORE
Market Overview

Global Acute Agitation and Aggression Treatment market are expected to witness a CAGR of 4.9% during the forecast period. Certain factors that are driving the market growth include a rise in the burden of mental illness and an increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatment for agitation.

According to the statistics provided by the Mental Health Foundation in 2018, mental health problems are one of the primary causes of rising medical concerns. In addition, according to the United States Census Bureau’s Statistics, as of 2017, the total number of people aged 65 and older exceeds 50 million, and between 2020-2030, the number of the elderly population is projected to increase by almost 18 million. Although much smaller in the total size, the number of people aged between 85 years and older is expected to be more than tripled, from an estimated 6 million in 2017 to nearly 20 million by 2060. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the elderly population.

Scope of the Report

Agitation is generally defined as excessive verbal and/or motor behavior. It can escalate to aggression, which can be either verbal (vicious cursing and threats) or physical (toward objects or people). The scope of the market studied includes the drugs which acutely agitated patients are offered.

Key Market Trends

Anti-psychotics are Expected to Hold Significant Market Share in the Drug Class Segment

The typical antipsychotics cause sedation, given a high enough dose. Haloperidol, a high potency butyrophenone, has been frequently used as an intramuscular as-needed medication for agitation and aggressive behavior in an emergency department setting for a wide variety of patients. Droperidol, another antipsychotic in the butyrophenone class, is not approved by the US Food and Drug Administration for psychiatric conditions but has been used for sedating agitated patients in an emergency room setting.

North America Dominates the Market and Expected to do Same in the Forecast Period

As per the Mental Health America, more than 44 million American adults have a mental health condition (2017). The most commonly reported agents are benzodiazepines, followed by butyrophenone antipsychotics (e.g., haloperidol, droperidol) as reported by directors of emergency medicine residencies and pediatric emergency medicine fellowships in the United States. Moreover, within the United States, approximately 5.7 million people are living with dementia (Alzheimer’s Association, 2018). All these factors are expected to drive market growth in the region.

Competitive Landscape

The global acute agitation and aggression treatment market is moderately competitive and consists of a few major players. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Bristol-Myers Squibb, among others, hold the substantial market share in the Acute Agitation and Aggression Treatment market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Holdings
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in geriatric population and increase in agitation in patients
4.2.2 Increase in focus on creating awareness about agitation and aggression
4.2.3 Ongoing research on the development of novel treatment for agitation
4.3 Market Restraints
4.3.1 Preference for non-pharmacological interventions
4.3.2 Social stigma associated with mental illness
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Route of Administration
5.1.1 Oral
5.1.2 Intramuscular
5.1.3 Others
5.2 By Drug Class
5.2.1 Anti-psychotics
5.2.2 Benzodiazepines
5.2.3 Others
5.3 By End Users
5.3.1 Hospitals & Ambulatory Surgical Centers
5.3.2 Psychiatric Care Facilities
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Pfizer, Inc.
6.1.3 Otsuka Holdings
6.1.4 GlaxoSmithKline
6.1.5 H. Lundbeck A/S
6.1.6 Johnson & Johnson
6.1.7 Bristol-Myers Squibb

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Otsuka Holdings
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Bristol-Myers Squibb
Note: Product cover images may vary from those shown